{"title":"Thermo Fisher to buy Olink for $3.1 billion","authors":"None Rick Mullin","doi":"10.1021/cen-10135-buscon14","DOIUrl":null,"url":null,"abstract":"Thermo Fisher Scientific will acquire the Swedish proteomics specialist Olink for $3.1 billion. Drawing on a library of 5,300 validated protein biomarkers, Olink has developed a high-throughput analysis platform for protein sequencing. The company has operations in the US and Asia as well as Europe. Olink’s proteomics capabilities will complement Thermo Fisher’s mass spectrometry and other assets in life sciences technology, Thermo Fisher CEO Marc N. Casper says in a press release announcing the deal. The sale is likely to be completed by mid-2024.","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"30 6","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"C&EN Global Enterprise","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1021/cen-10135-buscon14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Thermo Fisher Scientific will acquire the Swedish proteomics specialist Olink for $3.1 billion. Drawing on a library of 5,300 validated protein biomarkers, Olink has developed a high-throughput analysis platform for protein sequencing. The company has operations in the US and Asia as well as Europe. Olink’s proteomics capabilities will complement Thermo Fisher’s mass spectrometry and other assets in life sciences technology, Thermo Fisher CEO Marc N. Casper says in a press release announcing the deal. The sale is likely to be completed by mid-2024.
赛默飞世尔科技将以31亿美元收购瑞典蛋白质组学专家Olink。利用5300个经过验证的蛋白质生物标记物库，Olink开发了一个高通量的蛋白质测序分析平台。该公司在美国、亚洲和欧洲都有业务。赛默飞世尔首席执行官Marc N. Casper在宣布该交易的新闻发布会上表示，Olink的蛋白质组学能力将补充赛默飞世尔的质谱和其他生命科学技术资产。这笔交易可能会在2024年中期完成。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
